While recent studies in mice have confirmed that CSF1R inhibition decreased tumor growth in PDGFB-driven GBM, they also reported that it failed to show beneficial effects in mice bearing mesenchymal RAS-driven GBMs or other proneural and mesenchymal GBMs (129). This evidence concerns the gene CSF1R and glioblastoma.